Nykode Therapeutics ASA
Climate Impact & Sustainability Data (2023)
Reporting Period: 2023
Environmental Metrics
Total Carbon Emissions:5355 tCO2e (location based)
Scope 1 Emissions:0.46 tCO2e
Scope 2 Emissions:141.4 tCO2e (market based), 5.84 tCO2e (location based)
Scope 3 Emissions:5349 tCO2e
Waste Generated:3.337 tons
ESG Focus Areas
- Climate and GHG emissions
- Environmental impact and compliance
- Waste & Recycling
- Recruitment, Training, and Development
- Diversity, Equity, and Inclusion
- Employment Practices
- Health and Safety of our Employees
- Socially Responsible Practices and Trials
- Ethical Business Practices
- Regulatory Compliance
- Sustainable Supply Chain
Environmental Achievements
- Implemented simple GHG reduction initiatives.
- Refined approach to waste minimization.
Social Achievements
- Implemented an employee engagement survey.
- Continued DE&I Sounding Board initiatives.
Governance Achievements
- Strengthened governance structures to exceed regulatory requirements.
- Continued human rights due diligence with an independent third party.
Climate Goals & Targets
Environmental Challenges
- Many waste streams require specialized disposal methods, limiting opportunities for recycling.
- Relatively small-scale nature of operations limits environmental impact reduction opportunities.
Mitigation Strategies
- Implementing simple GHG reduction initiatives.
- Refining waste minimization approach.
- Establishing best practices in environmental stewardship.
Supply Chain Management
Responsible Procurement
- Adherence to Code of Conduct, focus on human rights, alignment with UN Guiding Principles on Business and Human Rights, and meeting requirements of the Norwegian Transparency Act.
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: SASB Biotechnology & Pharmaceuticals Standard (2023), GRI Standards’ (2021) Materiality Standard (GRI 3)